Lilly has acquired a Boston biotechnology company for $1.5 billion, according to a headline published by NBC Boston on Nov. 17.

The supplied material does not identify the company being purchased or describe its business. It also provides no transaction terms beyond the headline price, closing information or details about any effects on Boston operations.

The summary accompanying the headline concerns an unrelated municipal story rather than the acquisition. Without the underlying business report or another relevant source, there is not enough verified information to produce a fuller account of the deal.